$NRIX 8-K SEC Filings

Filed On	Filing
13 Oct 2026	8-K: Results of Operations and Financial Condition Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
09 Jul 2026	8-K: Results of Operations and Financial Condition
11 Jun 2026	8-K: Regulation FD Disclosure; Other Events
08 Jun 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
15 May 2026	8-K: Submission of Matters to a Vote of Security Holders
08 Apr 2026	8-K: Results of Operations and Financial Condition
06 Mar 2026	8-K: Other Events
28 Jan 2026	8-K: Results of Operations and Financial Condition
12 Jan 2026	8-K: Regulation FD Disclosure
09 Dec 2025	8-K: Regulation FD Disclosure; Other Events
10 Nov 2025	8-K: Departure/Election of Directors or Officers; Compensation
22 Oct 2025	8-K: Other Events
22 Oct 2025	8-K: Regulation FD Disclosure; Other Events
09 Oct 2025	8-K: Results of Operations and Financial Condition
03 Sep 2025	8-K: Regulation FD Disclosure
22 Aug 2025	8-K: Departure/Election of Directors or Officers; Compensation
09 Jul 2025	8-K: Results of Operations and Financial Condition
12 Jun 2025	8-K: Regulation FD Disclosure; Other Events
19 May 2025	8-K: Submission of Matters to a Vote of Security Holders
08 Apr 2025	8-K: Results of Operations and Financial Condition

Comments